Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deven Parmar

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 30, 2024
The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patientsKung-Hung Lin, Nuria Amigo, Pablo Ortiz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2023
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled AnalysisMohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 27, 2023
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipientsMohammad Shadab Siddiqui, Deven Parmar, Farheen Shaikh, et al.
Clinical and Translational Gastroenterology|March 26, 2021
A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary CholangitisRaj Vuppalanchi, Ma Saraí González-Huezo, Ramon Payan-Olivas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2020
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic SteatohepatitisMohammad Shadab Siddiqui, Michael O Idowu, Deven Parmar, et al.
Clinical Therapeutics|October 30, 2025
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled AsthmaChintan Patel, Diptikant Sahoo, Vaishal Sheth, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 TrialSamer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Respiratory Medicine|August 4, 2025
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patientsChintan Patel, Vaishal Sheth, Ravi Koppula, et al.
Indian Journal of Pharmacology|September 9, 2024
Advancing pediatric drug development in South Asia: Current landscape and vision for the futureRajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Saroglitazar 4 Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 StudyArun Sanyal, Soham Doshi, Nitin Behl, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 30, 2024
The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patientsKung-Hung Lin, Nuria Amigo, Pablo Ortiz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2023
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled AnalysisMohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 27, 2023
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipientsMohammad Shadab Siddiqui, Deven Parmar, Farheen Shaikh, et al.
Clinical and Translational Gastroenterology|March 26, 2021
A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary CholangitisRaj Vuppalanchi, Ma Saraí González-Huezo, Ramon Payan-Olivas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2020
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic SteatohepatitisMohammad Shadab Siddiqui, Michael O Idowu, Deven Parmar, et al.
Clinical Therapeutics|October 30, 2025
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled AsthmaChintan Patel, Diptikant Sahoo, Vaishal Sheth, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 TrialSamer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Respiratory Medicine|August 4, 2025
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patientsChintan Patel, Vaishal Sheth, Ravi Koppula, et al.
Indian Journal of Pharmacology|September 9, 2024
Advancing pediatric drug development in South Asia: Current landscape and vision for the futureRajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Saroglitazar 4 Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 StudyArun Sanyal, Soham Doshi, Nitin Behl, et al.
Pageof 4